Jason Shpilsky, MD

Penn Medicine Clinician of Medicine (Hematology-Oncology)
Attending , Penn Presbyterian Medical Center
Medical Oncologist, Penn Medicine Cherry Hill
Medical Oncologist , Penn Medicine Sewell
Department: Medicine
Contact information
Penn Medicine Cherry Hill
1865 Route 70 East
Cherry Hill, NJ 08003
1865 Route 70 East
Cherry Hill, NJ 08003
Education:
BS (Biochemistry and Molecular Biology, with honors and distinction )
Pennsylvania State University , 2011.
MD (Medicine)
Lewis Katz School of Medicine at Temple University , 2015.
Permanent linkBS (Biochemistry and Molecular Biology, with honors and distinction )
Pennsylvania State University , 2011.
MD (Medicine)
Lewis Katz School of Medicine at Temple University , 2015.
Selected Publications
Demissei BG, Ko K, Huang A, Lee DJ, Doucette AG, Smith AM, Wilcox NS, Reibel J, Sun L, Agarwal M, Haas NB, Hollis G, Shpilsky JE, Takvorian SU, Vaughn DJ, Chen J, Hubbard RA, Powell-Wiley T, Yancy C, Narayan V, Ky B.: Social Determinants of Health Mediate Racial Disparities in Cardiovascular Disease in Men With Prostate Cancer. JACC CardioOncol 6(3): 390-401, Jun 2024.Roberts DA, Faig J, Bodio-Downey K, Shpilsky J, Leahy K, Wischhusen J, Giordano S, Acharya U, Drews R, Dougherty D, Lathan C, Rangachari D.: Training Hematologists/Oncologists for the Academic-Community Hybrid: Creating a Fellowship Framework for the Future. JCO Oncol Pract 19(6): e927-e934. Jun 2023.
Shpilsky J, Stevens J, Bubley G.: An up-to-date evaluation of abiraterone for the treatment of prostate cancer. Expert Opin Pharmacother 22(10): 1227-1234. Jul 2021.
Rakowsky S, Flashner BM, Doolin J, Reese Z, Shpilsky J, Yang S, Smith CC, Graham K.: Five Questions for Residency Leadership in the Time of COVID-19: Reflections of Chief Medical Residents From an Internal Medicine Program. Acad Med 95(8): 1152-1154, Aug 2020.
Rangachari D, To C, Shpilsky JE, VanderLaan PA, Kobayashi SS, Mushajiang M, Lau CJ, Paweletz CP, Oxnard GR, Jänne PA, Costa DB.: EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples. J Thorac Oncol 14(11): 1995-2002, Nov 2019.